Pfister Roman, Diedrichs Holger, Schiedermair Anne, Rosenkranz Stephan, Hellmich Martin, Erdmann Erland, Schneider Christian Alfons
Department III of Internal Medicine, University of Cologne, Germany.
Eur J Heart Fail. 2008 Mar;10(3):315-20. doi: 10.1016/j.ejheart.2008.01.009. Epub 2008 Mar 4.
Multi-marker risk scores accurately predict prognosis in heart failure patients but calculation is complex.
To compare the prognostic accuracy of the Seattle Heart Failure Survival Score (SHFS) and a model derived from the CHARM programme, with laboratory parameters NT-proBNP and glomerular filtration rate (GFR).
In a sample of 290 heart failure patients, 39 patients died, 22 were hospitalised with acute heart failure and 4 underwent urgent cardiac transplantation during a median follow-up of 498 days. NT-proBNP, GFR, CHARM and SHFS showed an AUC for an endpoint during 1-year of 0.80, 0.72, 0.79 and 0.69, respectively. The hazard ratio for an endpoint during follow-up was 2.1, 2.6, 1.9 and 2.1 per 1 SD increase of log NT-proBNP and CHARM and per 1 SD decrease of GFR and SHFS, respectively. In multivariate analysis, log NT-proBNP and GFR added independent prognostic information to CHARM and SHFS, respectively.
NT-proBNP and GFR independently predicted endpoint-free survival in systolic heart failure patients, with NT-proBNP being superior and equally predictive to the SHFS and CHARM score, respectively. Assessment of both laboratory markers can simplify prognostic stratification, addition to multi-marker scores should be evaluated.
多标志物风险评分可准确预测心力衰竭患者的预后,但计算复杂。
比较西雅图心力衰竭生存评分(SHFS)和源自CHARM研究项目的模型与实验室参数N末端B型利钠肽原(NT-proBNP)和肾小球滤过率(GFR)的预后准确性。
在290例心力衰竭患者样本中,在中位随访498天期间,39例患者死亡,22例因急性心力衰竭住院,4例接受了紧急心脏移植。NT-proBNP、GFR、CHARM和SHFS在1年内终点事件的曲线下面积(AUC)分别为0.80、0.72、0.79和0.69。随访期间终点事件的风险比,每log NT-proBNP和CHARM升高1个标准差分别为2.1、2.6、1.9和2.1,每GFR和SHFS降低1个标准差分别为2.1、2.6、1.9和2.1。在多变量分析中,log NT-proBNP和GFR分别为CHARM和SHFS增加了独立的预后信息。
NT-proBNP和GFR独立预测收缩性心力衰竭患者无终点事件生存,NT-proBNP分别优于SHFS和CHARM评分且具有同等预测性。评估这两种实验室标志物可简化预后分层,多标志物评分的附加作用应予以评估。